Uri Kedem

Bluebricks enables DevOps to compile, download, and deploy blueprints instantly within the company cloud account while enforcing policies created by the Cloud Center of Excellence.

MDClone offers an innovative, self-service data analytics environment powering exploration, discovery, and collaboration throughout healthcare ecosystems, cross-institutionally, and globally. The powerful underlying infrastructure of the MDClone ADAMS Platform allows users to overcome common barriers in healthcare in order to organize, access, and protect the privacy of patient data while accelerating research, improving operations and quality, and driving innovation to deliver better patient outcomes. Unlike traditional analytics platforms, the MDClone ADAMS Platform introduces a fundamentally different approach to healthcare data analysis, exploration, and action that embraces a fast, non-linear, and fluid process for dynamic data exploration. Platform capabilities include synthetic data, continuous data feeds, longitudinal data, unstructured data, flexible infrastructure, and 3rd party tool integration. Founded in Israel in 2016, MDClone serves major health systems, payers, and life science customers in the United States, Canada, and Israel including the VHA Ecosystem (Dept of Veterans Affairs), The National Institutes of Health, Intermountain Healthcare, Regenstrief Institute, The Ottawa Hospital, and Sheba Medical Center, among other notable institutions. For more information, visit mdclone.com.

Theranica is a neuromodulation therapeutics company dedicated to creating effective, safe, affordable, and low-side-effect therapies for idiopathic pain conditions. Our initial focus is on migraine, one of the most common neurologic disorders affecting over 1 billion people, with a high prevalence and morbidity, especially among adolescents and females. The company’s award-winning flagship Nerivio® REN wearable is changing the game for migraine sufferers, especially the 100 million adolescents facing this complex and non-curable disease. Nerivio is the first and only REN wearable that harnesses the natural power of the brain to shut off migraine symptoms without the use of drugs. With early intervention being key, Nerivio offers a safe and side-effect-free alternative, empowering adolescents to take control of their health and providing a foundation for complete migraine care as they transition into adulthood. Theranica is a neuromodulation therapeutics company dedicated to creating effective, safe, affordable, low-side-effect therapies for idiopathic pain conditions. The Nerivio REN wearable is FDA-cleared and CE-marked for the acute and/or preventive treatment of migraine with or without aura in people 8 years of age or older. It has been used in more than 650,000 migraine treatments in the US, including by adolescents and veterans living with migraine. Learn more by visiting our websites, theranica.com, and nerivio.com.

aMoon is a global HealthTech and Life Sciences investment fund based in Israel. As Israel’s largest HealthTech fund, with $1.1 billion AUM, we partner with outstanding entrepreneurs who harness groundbreaking science and technology to transform healthcare. Together with our portfolio companies, we work tirelessly to advance solutions that will help people live healthier, better lives. We harness our unique team of over 50 scientists, physicians and entrepreneurs and our global network of investors and industry leaders to build bridges between our portfolio companies and global tech, finance and medical research hubs to help entrepreneurs turn their vision into reality. Through our Velocity Fund we invest in companies pursuing disruptive, cutting-edge technologies as early as venture formation through Series A. Our Growth Fund invests in later-stage companies that are either generating revenue in growth rounds, pre-IPO rounds or in pivotal clinical trials.

Kiteworks mission is to empower organizations to effectively manage risk in every send, share, receive, and save of sensitive content. To this end, we created a platform that delivers content governance, compliance, and protection to customers. The platform unifies, tracks, controls and secures sensitive content moving within, into, and out of their organization, significantly improving risk management and ensuring regulatory compliance on all sensitive content communications.

Bluebricks enables DevOps to compile, download, and deploy blueprints instantly within the company cloud account while enforcing policies created by the Cloud Center of Excellence.

Seed-stage venture capital firm based in Boston and New York City investing in ambitious founders leveraging the power of AI. With over $1 billion under management across six seed funds and seven pre-seed funds, portfolio companies include BetterCloud, BitSight, Bowery, Chief, Codecademy (acq: SKILL), FalconX, Firebase (acq: GOOG), Infracommerce (BVMF: IFCM3), MadeiraMadeira, MongoDB (NASDAQ: MDB), Open English, Plastiq, and Splice.

MDClone offers an innovative, self-service data analytics environment powering exploration, discovery, and collaboration throughout healthcare ecosystems, cross-institutionally, and globally. The powerful underlying infrastructure of the MDClone ADAMS Platform allows users to overcome common barriers in healthcare in order to organize, access, and protect the privacy of patient data while accelerating research, improving operations and quality, and driving innovation to deliver better patient outcomes. Unlike traditional analytics platforms, the MDClone ADAMS Platform introduces a fundamentally different approach to healthcare data analysis, exploration, and action that embraces a fast, non-linear, and fluid process for dynamic data exploration. Platform capabilities include synthetic data, continuous data feeds, longitudinal data, unstructured data, flexible infrastructure, and 3rd party tool integration. Founded in Israel in 2016, MDClone serves major health systems, payers, and life science customers in the United States, Canada, and Israel including the VHA Ecosystem (Dept of Veterans Affairs), The National Institutes of Health, Intermountain Healthcare, Regenstrief Institute, The Ottawa Hospital, and Sheba Medical Center, among other notable institutions. For more information, visit mdclone.com.

Theranica is a neuromodulation therapeutics company dedicated to creating effective, safe, affordable, and low-side-effect therapies for idiopathic pain conditions. Our initial focus is on migraine, one of the most common neurologic disorders affecting over 1 billion people, with a high prevalence and morbidity, especially among adolescents and females. The company’s award-winning flagship Nerivio® REN wearable is changing the game for migraine sufferers, especially the 100 million adolescents facing this complex and non-curable disease. Nerivio is the first and only REN wearable that harnesses the natural power of the brain to shut off migraine symptoms without the use of drugs. With early intervention being key, Nerivio offers a safe and side-effect-free alternative, empowering adolescents to take control of their health and providing a foundation for complete migraine care as they transition into adulthood. Theranica is a neuromodulation therapeutics company dedicated to creating effective, safe, affordable, low-side-effect therapies for idiopathic pain conditions. The Nerivio REN wearable is FDA-cleared and CE-marked for the acute and/or preventive treatment of migraine with or without aura in people 8 years of age or older. It has been used in more than 650,000 migraine treatments in the US, including by adolescents and veterans living with migraine. Learn more by visiting our websites, theranica.com, and nerivio.com.